Aastrom (ASTM) Slammed on Staff Cut, New Development Focus

March 27, 2013 9:38 AM EDT Send to a Friend
Aastrom Biosciences, Inc. (Nasdaq: ASTM) shares are getting slammed in early trading Wednesday following an earlier announcement that it would be slashing staff by 50 percent and refocusing resources on development of ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). Shares are down about 30 percent early.

For more color on the announcement, click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Momentum Movers, Trader Talk, Trading Halts

Add Your Comment